Deutsche Bank Ag\ Rigel Pharmaceuticals Inc Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.12 - $1.57 $3,386 - $4,747	3,024 Added 3.71%	84,552 $125,000
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.56 $1,876 - $4,065	2,606 Added 3.3%	81,528 $118,000
Q3 2023 Nov 09, 2023	BUY	$1.07 - $1.39 $16,158 - $20,990	15,101 Added 23.66%	78,922 $85,000
Q2 2023 Aug 14, 2023	SELL	$1.12 - $1.82 $55,438 - $90,088	-49,499 Reduced 43.68%	63,821 $82,000
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $46,343 - $74,150	37,075 Added 48.63%	113,320 $149,000
Q4 2022 Feb 13, 2023	BUY	$0.67 - $11.9 $773 - $13,744	1,155 Added 1.54%	76,245 $114,000
Q3 2022 Nov 14, 2022	SELL	$1.1 - $12.2 $12,681 - $140,653	-11,529 Reduced 13.31%	75,090 $89,000
Q2 2022 Aug 11, 2022	SELL	$0.67 - $3.19 $7,848 - $37,367	-11,714 Reduced 11.91%	86,619 $98,000
Q1 2022 May 13, 2022	SELL	$2.22 - $3.45 $30,231 - $46,982	-13,618 Reduced 12.16%	98,333 $294,000
Q4 2021 Feb 11, 2022	BUY	$2.36 - $3.57 $12,949 - $19,588	5,487 Added 5.15%	111,951 $297,000
Q3 2021 Nov 04, 2021	SELL	$3.5 - $4.5 $11,077 - $14,242	-3,165 Reduced 2.89%	106,464 $387,000
Q2 2021 Aug 11, 2021	SELL	$3.09 - $4.54 $22,955 - $33,727	-7,429 Reduced 6.35%	109,629 $476,000
Q1 2021 May 13, 2021	SELL	$3.35 - $4.93 $34,662 - $51,010	-10,347 Reduced 8.12%	117,058 $400,000
Q4 2020 Feb 16, 2021	BUY	$2.35 - $3.74 $6,770 - $10,774	2,881 Added 2.31%	127,405 $446,000
Q3 2020 Nov 12, 2020	BUY	$1.78 - $4.13 $67,841 - $157,406	38,113 Added 44.11%	124,524 $299,000
Q2 2020 Aug 13, 2020	BUY	$1.41 - $2.05 $41,186 - $59,880	29,210 Added 51.07%	86,411 $158,000
Q1 2020 May 14, 2020	SELL	$1.27 - $3.0 $657,057 - $1.55 Million	-517,368 Reduced 90.04%	57,201 $90,000
Q4 2019 Feb 14, 2020	BUY	$1.6 - $2.43 $93,577 - $142,120	58,486 Added 11.33%	574,569 $1.23 Million
Q3 2019 Nov 14, 2019	SELL	$1.63 - $2.62 $1.05 Million - $1.69 Million	-643,771 Reduced 55.5%	516,083 $963,000
Q2 2019 Aug 14, 2019	SELL	$2.02 - $2.61 $1.61 Million - $2.09 Million	-799,318 Reduced 40.8%	1,159,854 $3.03 Million
Q1 2019 May 15, 2019	BUY	$2.0 - $2.65 $796,018 - $1.05 Million	398,009 Added 25.49%	1,959,172 $5.03 Million
Q4 2018 Feb 14, 2019	SELL	$2.08 - $3.36 $143,948 - $232,532	-69,206 Reduced 4.24%	1,561,163 $3.59 Million
Q3 2018 Dec 21, 2021	BUY	$2.6 - $3.59 $816,257 - $1.13 Million	313,945 Added 23.85%	1,630,369 $5.23 Million
Q3 2018 Nov 14, 2018	SELL	$2.6 - $3.59 $817,159 - $1.13 Million	-314,292 Reduced 19.27%	1,316,424 $4.22 Million
Q2 2018 Apr 21, 2020	BUY	$2.83 - $4.11 $229,343 - $333,074	81,040 Added 5.23%	1,630,716 $4.61 Million
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $688,502 - $999,909	243,287 Added 18.62%	1,549,676 $4.39 Million
Q1 2018 Oct 18, 2019	BUY	$3.54 - $4.54 $940,025 - $1.21 Million	265,544 Added 25.51%	1,306,389 $4.62 Million
Q1 2018 May 15, 2018	SELL	$3.54 - $4.54 $130,335 - $167,153	-36,818 Reduced 3.42%	1,040,845 $3.68 Million
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $2.54 Million - $3.37 Million	784,847 Added 268.03%	1,077,663 $4.18 Million
Q3 2017 Nov 14, 2017	BUY	$2.18 - $2.57 $638,338 - $752,537	292,816	292,816 $742,000

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account